Anti-PD-1, anti-VEGF, and temozolomide therapy in a patient with recurrent glioblastoma: a case report

BACKGROUND: Patients suffering from postoperative recurrent glioblastoma have an extremely unfavorable outcome because there are no proven therapeutic options. The median overall survival for those with relapsed glioblastoma after surgery is only 7.5 months. Case presentation: Between March 2015 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Can, Zuo, Wenwei, Yang, Pan, Zhang, Yanling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479856/
https://www.ncbi.nlm.nih.gov/pubmed/32883128
http://dx.doi.org/10.1177/0300060520951395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479856/
https://www.ncbi.nlm.nih.gov/pubmed/32883128
http://dx.doi.org/10.1177/0300060520951395

Ejemplares similares